Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction

Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * Recent myocardial infarction. Evidence of significant myocardial necrosis defined as a rise in troponin level \> 99th Percentile ULN (upper limit of normal). In addition, at least one of the following criteria must be met: * Symptoms of ischemia. * ECG changes indicative of new ischemia (new ST-T changes or new Left bundle branch block (LBBB)) * Imaging evidence of new regional wall motion abnormality. * Estimated Glomerular Filtration Rate (eGFR)\> 30 ml/min/1.73 m2. * Blood pressure before first drug dosing \>110/70 mmHg. Exclusion Criteria: * Known allergy to sodium/glucose cotransporter 2 (SGLT2) inhibitors. * Patients with poor echocardiographic views. * Hemodynamic instability as defined by intravenous administration of catecholamine. * \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea. * Pregnant women or females of childbearing age without adequate contraceptive methods. * Acute symptomatic urinary tract infection (UTI) or genital infection * Patients currently being treated with any SGLT-2 inhibitor or having received treatment with any SGLT-2 inhibitor within the 4 weeks before the screening visit. * Patient with a previous myocardial ischemic event or previous heart failure. * Patients with significant valvular dysfunction.